China Resources Pharmaceutical Group Limited (Stock Code: 3320) announced that its subsidiary, CR Boya Bio-pharmaceutical, has disclosed unaudited results for the nine months ended 30 September 2025. CR Boya Bio-pharmaceutical is listed on the Shenzhen Stock Exchange, with China Resources Pharmaceutical Group Limited indirectly holding approximately 30.48% of its total share capital and 41.79% of its voting rights.

According to the unaudited financial information prepared under PRC Generally Accepted Accounting Principles, CR Boya Bio-pharmaceutical reported revenue of RMB 1,473,924,123.26 for the reporting period and a net profit of RMB 343,042,957.61. Net cash and cash equivalents decreased by RMB 536,817,463.21 from the start of the year, ending at RMB 761,753,926.76 as of 30 September 2025. Total assets stood at RMB 8,727,110,907.17, while total liabilities reached RMB 1,054,662,143.39, bringing the company’s owner’s equity to RMB 7,672,448,763.78.

The announcement emphasizes that the figures remain subject to further review or audit and do not fully represent the operating or financial position of China Resources Pharmaceutical Group Limited as a whole. Investors are advised to refer to the original quarterly report published by CR Boya Bio-pharmaceutical on the Shenzhen Stock Exchange website for further details.